# Phase II Study of Ofatumumab Plus Ifosfamide, Carboplatin, Etoposide (ICE) or Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL)

> **NCT00823719** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 61 (actual)

## Conditions studied

- Lymphoma, Large-Cell, Diffuse

## Interventions

- **DRUG:** ofatumumab + ICE
- **DRUG:** ofatumumab + DHAP

## Key facts

- **NCT ID:** NCT00823719
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2011-07
- **Final completion:** 2011-09
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2013-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00823719

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00823719, "Phase II Study of Ofatumumab Plus Ifosfamide, Carboplatin, Etoposide (ICE) or Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00823719. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*